PMID- 28924126
OWN - NLM
STAT- MEDLINE
DCOM- 20180411
LR  - 20181202
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 56
IP  - 20
DP  - 2017 Oct 15
TI  - Development of Epstein-Barr Virus-related Primary Diffuse Large B-cell Lymphoma 
      of the Central Nervous System in a Patient with Peripheral T-cell Lymphoma, Not 
      Otherwise Specified after Mogamulizumab Treatment.
PG  - 2759-2763
LID - 10.2169/internalmedicine.8781-16 [doi]
AB  - Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 
      (CCR4) antibody that exerts an anti-tumor immune effect against various tumors 
      through a suppressive effect on regulatory T-cells. We herein report a patient 
      with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related 
      primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) 
      after mogamulizumab therapy. Our experience should alert physicians to the 
      possibility of the development of EBV-related CNS DLBCL in patients treated for 
      primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab 
      is ineffective for the prophylaxis of EBV-related lymphomas.
FAU - Tanaka, Hiroaki
AU  - Tanaka H
AD  - Department of Hematology, Asahi General Hospital, Japan.
FAU - Aoki, Hanako
AU  - Aoki H
AD  - Department of Internal Medicine, Asahi General Hospital, Japan.
FAU - Sugita, Yasumasa
AU  - Sugita Y
AD  - Department of Hematology, Asahi General Hospital, Japan.
FAU - Shimizu, Ryo
AU  - Shimizu R
AD  - Department of Hematology, Asahi General Hospital, Japan.
FAU - Kiko, Katsunari
AU  - Kiko K
AD  - Department of Neurosurgery, Asahi General Hospital, Japan.
FAU - Mochida, Hidetoshi
AU  - Mochida H
AD  - Department of Neurosurgery, Asahi General Hospital, Japan.
FAU - Suzuki, Yoshio
AU  - Suzuki Y
AD  - Department of Diagnostic Pathology, Asahi General Hospital, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20170915
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, CCR4)
RN  - YI437801BE (mogamulizumab)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*adverse effects
MH  - Central Nervous System Diseases/*etiology/virology
MH  - Female
MH  - *Herpesvirus 4, Human
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy
MH  - Lymphoma, T-Cell, Peripheral/*etiology/virology
MH  - Male
MH  - Receptors, CCR4/immunology
MH  - T-Lymphocytes, Regulatory
PMC - PMC5675939
OTO - NOTNLM
OT  - CNS DLBCL
OT  - EBV
OT  - PTCL-NOS
OT  - mogamulizumab
OT  - secondary malignancy
EDAT- 2017/09/20 06:00
MHDA- 2018/04/12 06:00
PMCR- 2017/10/15
CRDT- 2017/09/20 06:00
PHST- 2017/09/20 06:00 [pubmed]
PHST- 2018/04/12 06:00 [medline]
PHST- 2017/09/20 06:00 [entrez]
PHST- 2017/10/15 00:00 [pmc-release]
AID - 10.2169/internalmedicine.8781-16 [doi]
PST - ppublish
SO  - Intern Med. 2017 Oct 15;56(20):2759-2763. doi: 10.2169/internalmedicine.8781-16. 
      Epub 2017 Sep 15.